Jonathan Freeman Net Worth

Jonathan Freeman biography

Dr. Jonathan Freeman, Ph.D., is Independent Director of the company. He has serves as the Chief Business Officer at Vedanta Biosciences, a privately-held company developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Previously, Dr. Freeman was Senior Vice President, Head of Strategy Development and Portfolio Management at Merck KGaA. During his tenure, Jonathan was responsible for the portfolio and strategic shift that repositioned Merck as a major player in the immuno-oncology space. Prior to that role, he was the Head of Global Business Development and Licensing at Merck executing more than 30 transactions and structured financings. Prior to his roles at Merck, Jonathan served in senior positions at Baxter and Serono, in M&A and, Corporate and Business Development, respectively. Jonathan holds a First Class Honours in Biochemistry and an MA from Cambridge University, UK, a PhD in cancer research from the Imperial Cancer Research Fund (now CRUK), and an MBA with a finance major from Webster University, St. Louis. He held various post-doctoral positions in the Swiss Institute for Cancer Research (ISREC), and the Geneva Medical School (CMU).

What's Jonathan Freeman's mailing address?

Jonathan's mailing address filed with the SEC is C/O PHIO PHARMACEUTICALS CORP., 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA, 01752.

Insiders trading at Phio Pharmaceuticals

Over the last 6 years, insiders at Phio Pharmaceuticals have traded over $0 worth of Phio Pharmaceuticals stock and bought 37,351 units worth $53,368 . The most active insiders traders include Geert Cauwenbergh, Keith L Brownlie y Patricia A Bradford. On average, Phio Pharmaceuticals executives and independent directors trade stock every 82 days with the average trade being worth of $6,130. The most recent stock trade was executed by Robert J Bitterman on 7 June 2024, trading 1,000 units of PHIO stock currently worth $740.

What does Phio Pharmaceuticals do?

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Phio Pharmaceuticals executives and stock owners

Phio Pharmaceuticals executives and other stock owners filed with the SEC include:

• Geert Cauwenbergh,
  Director
• Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D.,
  Pres, CEO & Director
• Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc,
  Pres, CEO & Director
• Tamara McGrillen,
  IR Contact Officer
• Curtis Lockshin,
  Independent Director
• Jonathan Freeman,
  Independent Director
• H. Paul Dorman,
  Independent Director
• John Barrett,
  Chief Development Officer
• Gerrit Dispersyn,
  President, Chief Executive Officer, Chief Operating Officer
• Robert Bitterman,
  Independence Chairman of the Board
• Caitlin Kontulis,
  VP of Fin. & Admin. and Sec.
• Patricia A Bradford,
  Director
• Robert L Ferrara,
  Director
• Keith L Brownlie,
  Director
• Caitlin Kontulis,
  Secretary & VP Finance & Admin
• Robert M. Infarinato,
  VP, Chief Financial Officer